Aldeyra Therapeutics IncNASDAQ:ALDX
- LAST PRICE3.8700
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots3.7500/ 1
- Ask / Lots4.1000/ 16
- Open / Previous Close3.9300 / 3.8700
- Day Range
- 52 Week Range
- Volume227,886
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ALDX |
|---|---|---|
| 09:32 ET | 3085 | 3.91 |
| 09:38 ET | 993 | 3.935 |
| 09:39 ET | 4699 | 3.96 |
| 09:41 ET | 600 | 3.95 |
| 09:43 ET | 250 | 3.95 |
| 09:45 ET | 147 | 3.9599 |
| 09:48 ET | 300 | 3.92 |
| 09:50 ET | 200 | 3.92 |
| 09:52 ET | 556 | 3.93 |
| 09:57 ET | 100 | 3.935 |
| 09:59 ET | 500 | 3.92 |
| 10:03 ET | 1109 | 3.93 |
| 10:06 ET | 500 | 3.935 |
| 10:08 ET | 11137 | 3.97 |
| 10:10 ET | 344 | 3.96 |
| 10:14 ET | 372 | 3.95 |
| 10:15 ET | 1810 | 3.95 |
| 10:19 ET | 200 | 3.955 |
| 10:24 ET | 313 | 3.96 |
| 10:26 ET | 300 | 3.9605 |
| 10:28 ET | 500 | 3.9607 |
| 10:30 ET | 100 | 3.9603 |
| 10:33 ET | 200 | 3.965 |
| 10:35 ET | 803 | 3.98 |
| 10:39 ET | 1200 | 3.97 |
| 10:42 ET | 100 | 3.97 |
| 10:46 ET | 500 | 3.97 |
| 10:48 ET | 1662 | 3.975 |
| 10:51 ET | 205 | 3.98 |
| 10:55 ET | 600 | 3.98 |
| 11:00 ET | 1881 | 3.97 |
| 11:02 ET | 700 | 3.9503 |
| 11:04 ET | 441 | 3.95 |
| 11:08 ET | 7000 | 3.95 |
| 11:11 ET | 3660 | 3.94 |
| 11:13 ET | 201 | 3.92 |
| 11:15 ET | 1042 | 3.92 |
| 11:20 ET | 256 | 3.91 |
| 11:22 ET | 1355 | 3.92 |
| 11:31 ET | 719 | 3.91 |
| 11:33 ET | 400 | 3.91 |
| 11:40 ET | 350 | 3.9 |
| 11:42 ET | 100 | 3.9 |
| 11:44 ET | 600 | 3.92 |
| 11:45 ET | 100 | 3.91 |
| 11:47 ET | 100 | 3.91 |
| 11:49 ET | 200 | 3.91 |
| 11:54 ET | 100 | 3.9 |
| 12:00 ET | 6950 | 3.91 |
| 12:02 ET | 1661 | 3.91 |
| 12:05 ET | 100 | 3.905 |
| 12:07 ET | 100 | 3.905 |
| 12:09 ET | 769 | 3.905 |
| 12:12 ET | 188 | 3.9 |
| 12:16 ET | 200 | 3.9 |
| 12:20 ET | 100 | 3.9 |
| 12:25 ET | 200 | 3.9 |
| 12:34 ET | 400 | 3.9 |
| 12:45 ET | 500 | 3.9 |
| 12:52 ET | 900 | 3.9 |
| 12:54 ET | 100 | 3.9 |
| 01:03 ET | 100 | 3.905 |
| 01:06 ET | 100 | 3.9 |
| 01:08 ET | 614 | 3.905 |
| 01:12 ET | 100 | 3.9064 |
| 01:14 ET | 17937 | 3.9301 |
| 01:17 ET | 917 | 3.925 |
| 01:19 ET | 300 | 3.91 |
| 01:21 ET | 232 | 3.91 |
| 01:26 ET | 6304 | 3.9294 |
| 01:30 ET | 100 | 3.92 |
| 01:32 ET | 1250 | 3.9369 |
| 01:33 ET | 986 | 3.92 |
| 01:35 ET | 1130 | 3.9275 |
| 01:37 ET | 451 | 3.92 |
| 01:44 ET | 533 | 3.91 |
| 01:57 ET | 5000 | 3.9146 |
| 02:00 ET | 100 | 3.91 |
| 02:02 ET | 400 | 3.91 |
| 02:04 ET | 1084 | 3.9 |
| 02:06 ET | 100 | 3.9 |
| 02:08 ET | 103 | 3.9 |
| 02:15 ET | 100 | 3.9 |
| 02:20 ET | 1950 | 3.9 |
| 02:22 ET | 6097 | 3.89 |
| 02:24 ET | 8570 | 3.88 |
| 02:26 ET | 100 | 3.87 |
| 02:27 ET | 822 | 3.87 |
| 02:29 ET | 1381 | 3.87 |
| 02:31 ET | 471 | 3.87 |
| 02:36 ET | 500 | 3.87 |
| 02:40 ET | 500 | 3.87 |
| 02:42 ET | 200 | 3.87 |
| 02:44 ET | 700 | 3.87 |
| 02:47 ET | 100 | 3.87 |
| 02:49 ET | 1638 | 3.88 |
| 02:51 ET | 1140 | 3.88 |
| 02:54 ET | 220 | 3.875 |
| 02:56 ET | 1430 | 3.875 |
| 03:02 ET | 300 | 3.875 |
| 03:03 ET | 200 | 3.875 |
| 03:05 ET | 100 | 3.875 |
| 03:07 ET | 200 | 3.875 |
| 03:09 ET | 710 | 3.885 |
| 03:18 ET | 100 | 3.885 |
| 03:20 ET | 1422 | 3.87 |
| 03:23 ET | 283 | 3.87 |
| 03:25 ET | 100 | 3.87 |
| 03:27 ET | 100 | 3.87 |
| 03:30 ET | 100 | 3.87 |
| 03:34 ET | 200 | 3.87 |
| 03:36 ET | 400 | 3.87 |
| 03:41 ET | 1030 | 3.865 |
| 03:43 ET | 3408 | 3.855 |
| 03:45 ET | 900 | 3.85 |
| 03:48 ET | 200 | 3.85 |
| 03:50 ET | 4544 | 3.84 |
| 03:52 ET | 1205 | 3.84 |
| 03:54 ET | 544 | 3.845 |
| 03:56 ET | 4351 | 3.875 |
| 03:57 ET | 2808 | 3.855 |
| 03:59 ET | 22183 | 3.87 |
May 8, 2024
May 6, 2024
DJ Aldeyra Therapeutics Price Target Maintained With a $10.00/Share by Oppenheimer, from 7:57AM ET on Monday May 06, 2024 by Dow Jones
7:57AM ET on Monday May 06, 2024 by Dow JonesDJ Aldeyra Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co., from 6:48AM ET on Monday May 06, 2024 by Dow Jones
6:48AM ET on Monday May 06, 2024 by Dow Jones
Apr 25, 2024
Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day, from 7:00AM ET on Thursday Apr 25, 2024 by Dow Jones
7:00AM ET on Thursday Apr 25, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Aldeyra Therapeutics Inc | 229.9M | -7.6x | --- |
Design Therapeutics Inc | 235.0M | -4.0x | --- |
Pyxis Oncology Inc | 229.7M | -2.8x | --- |
Acumen Pharmaceuticals Inc | 216.3M | -3.4x | --- |
Eliem Therapeutics Inc | 228.9M | -14.7x | --- |
Prelude Therapeutics Inc | 226.3M | -2.2x | --- |
Company Information
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.
Contact Information
- Headquarters
- 131 HARTWELL AVENUE, SUITE 320LEXINGTON, MA, United States 02421
- Phone
- 781-761-4904
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Richard Douglas
- President, Chief Executive Officer, Director
- Todd Brady
- Senior Vice President - Finance, Interim Chief Financial Officer
- Bruce Greenberg
- Chief Development Officer
- Stephen Machatha
- Independent Director
- Ben Bronstein
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $234.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 59.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.38 |
EPS | $-0.51 |
Book Value | $2.02 |
P/E Ratio | -7.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
